FDA approves Merck’s Keytruda for lung cancer treatment

Keytruda, a lung cancer treatment medication manufactured by Merck was approved Oct. 24 by the U.S. Food and Drug Administration (FDA), reports The Wall Street Journal.

The medication, meant to treat patients with metastatic non-small cell lung cancer, can be used instead of chemotherapy for patients with this type of cancer.

Keytruda was initially approved in 2014 to treat melanoma and is in a clinical development program to determine if it can also treat 30 other tumor types.

To read more about the medication and how it will change how physicians treat lung cancer, follow the link below:

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

American College of Cardiology President B. Hadley Wilson, MD, discussed why the ACC and other leading cardiology groups are so eager to create a new, independent medical board. This has been a long-term goal for many years, he said, and now it may become a reality. 

Last week brought the latest in an occasional series of conversations on AI between governmental leaders and Big Tech honchos.

Programs managed by H-E-B, Kroger, Mark Cuban Cost Plus Drug Company and Walmart appear to offer the most options for CVD patients. When it comes to AFib and heart failure, however, researchers believe the choices could be improved. 

Trimed Popup
Trimed Popup